Salem Radio Network News Monday, November 16, 2026

Health

AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy

Carbonatix Pre-Player Loader

Audio By Carbonatix

Nov 16 (Reuters) – AstraZeneca said on Monday it has won two US drug approvals, an expanded bladder cancer use for its immunotherapy Imfinzi and a first-of-its-kind therapy for a rare muscle-weakening disorder.

• The US Food and Drug Administration approved Imfinzi, combined with enfortumab vedotin, a targeted therapy prior to surgery, for muscle-invasive bladder cancer patients who are ineligible for or have refused cisplatin-based chemotherapy

• The Imfinzi approval was based on a late-stage trial which showed the regimen cut the risk of cancer recurrence by 49% and the risk of death by 42%

• Imfinzi is already approved across more than 50 countries and is indicated for a range of cancers including lung and bladder

• The FDA also approved Klygefa, developed by AstraZeneca’s rare disease unit Alexion, for adults with generalised myasthenia gravis who carry antibodies that attack proteins on the nerves, disrupting communication with muscles

• Klygefa also won approval in the EU for the same indication on Monday, adding to its clearances in Japan and other countries for certain adults with gMG

(Reporting by Raechel Thankam Job in Bengaluru; Editing by Janane Venkatraman)

Previous
Next
The Media Line News
X CLOSE